BDR Pharma has launched BIAPENEM to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. The drug will be available in the market shortly.  

BDR Pharma was the first to identify and develop this product and conducted clinical studies in conjunction with some of the leading players in the critical care segment who co-sponsored these studies. BDR Pharma was also the first one to get the DCGI (Drug Controller General of India) approval for this drug. 

Raheel Shah, Director – Business Development, BDR Pharmaceuticals, said, “The drug will cover a broad spectrum of almost every infection and will be a great boon to the medical fraternity and patients. Firmly following the path of accessible and affordable care, we have categorically decided to market this wonder product and we will make arrangements to supply the product to the co-sponsors who will also market it under their brand name. We aim to meet the demand of every patient while maintaining the highest quality during these critical times through improved medical solutions.”

Biapenem is mainly prescribed to patients with intra-abdominal, lower respiratory or complicated urinary tract infections. It belongs to a critical parenteral carbapenem antibacterial agent. However, the dosage of BIAPEN is much lesser as compared to the existing class of Carbapenems. Thereby reducing the dosage quantity showing good clinical and bacteriological efficacy. Biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid).